JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us
このページは機械翻訳されています。他のページは英語で表示される場合があります。 View in English

STARD4 / EGFR軸をターゲットに成長を抑制し,肝細胞がんにおけるレンバチニブ耐性を克服する

  • 0Department of Pharmacy, Nanfang Hospital, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong 510515, China.
Genes & Diseases +

|

2025年8月20日

|

2025年8月20日

PubMedで要約を見る

まとめ

この要約は機械生成です。

STARD4はコレステロールに影響を与え,EGFRシグナリングを活性化することで,肝細胞がん (HCC) の成長とレンバチニブ耐性を促進する. STARD4を標的とした治療は,HCCの治療におけるレンバチニブの有効性を改善する可能性があります.

科学分野

  • 腫瘍学
  • 分子生物学
  • 生物化学

背景

  • 肝細胞癌 (HCC) は転移した癌で,レンバチニブ化学療法に耐性があることが多い.
  • レンバチニブ耐性メカニズムの理解は,HCCの治療結果の改善に不可欠です.

研究 の 目的

  • HCCの進行とレンバチニブ耐性におけるSTARD4の役割を調査する.
  • EGFR/PI3K/AKT経路がSTARD4を媒介する効果に関与するかを調査する.

主な方法

  • STARD4とEGFR発現のための臨床HC検体の分析
  • HCC 細胞系と異種移植に関する in vitro および in vivo 研究
  • コレステロールの輸送,EGFRのリン酸化,およびシグナル伝達経路の活性化に関する研究.

主要な成果

  • STARD4の発現はHCCの悪性腫瘍と相関し,腫瘍の成長とレンバチニブ耐性を促進する.
  • STARD4はコレステロールのホメオスタシスを調節し,EGFRのリン酸化に影響を与え,EGFR/PI3K/AKT経路を活性化します.
  • エロチニブによるEGFR阻害は,STARD4誘発のHCC進行を相殺した.

結論

  • STARD4は,コレステロールの調節とEGFR/PI3K/AKT経路の活性化により,HCCの成長とレンバチニブ耐性を誘発する.
  • STARD4は,HCCにおけるレンバチニブ耐性を予測する潜在的なバイオマーカーです.
  • STARD4は,HCCにおけるレンバチニブ耐性を克服するための有望な治療目標です.

キーワード:

関連する概念動画

Targeted Cancer Therapies 02:57

7.8K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle 02:38

6.6K

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Treatment Resistant Cancers 02:56

3.4K

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Combination Therapies and Personalized Medicine 02:50

5.1K

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Cancer Stem Cells and Tumor Maintenance 02:40

5.0K

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...